Integrated BioPharma, Inc. (INBP) — AI-Aktienanalyse

Integrated BioPharma, Inc. manufactures, distributes, and markets vitamins, nutritional supplements, and herbal products. It operates through contract manufacturing and other nutraceutical business lines, primarily in the United States and Luxembourg.

Unternehmensueberblick

Kurzfassung:

Integrated BioPharma, Inc. focuses on the manufacturing and distribution of vitamins, nutritional supplements, and herbal products, operating primarily in the United States and Luxembourg. With a presence in both contract manufacturing and direct distribution, the company caters to distributors, multilevel marketers, and specialized healthcare providers within the consumer defensive sector.

Ueber INBP

Integrated BioPharma, Inc., incorporated in 1980 and based in Hillside, New Jersey, operates within the consumer defensive sector, specifically in packaged foods. The company focuses on the manufacturing, distribution, marketing, and sale of vitamins, nutritional supplements, and herbal products. Its operations are divided into two segments: Contract Manufacturing and Other Business Lines. The Contract Manufacturing segment produces vitamins and nutritional supplements for distributors, multilevel marketers, and specialized healthcare providers. The Other Nutraceutical Businesses segment provides warehousing and fulfillment services, alongside distributing raw materials. Formerly known as Integrated Health Technologies, Inc., the company has established a presence in the United States and Luxembourg. Integrated BioPharma's business model caters to both B2B and potentially B2C channels, leveraging its manufacturing capabilities to supply a range of health and wellness products. The company's history reflects its evolution within the nutraceuticals market, adapting to changing consumer preferences and distribution models.

Investmentthese

Integrated BioPharma, Inc. presents a complex investment case, given its small market capitalization of $0.01 billion and negative profit margin of -0.4%. The company's low gross margin of 7.8% and negative ROE of -1.0% indicate profitability challenges. While the beta of 0.52 suggests lower volatility compared to the market, the high debt-to-equity ratio of 2.55 raises concerns about financial leverage. A key consideration is the company's ability to generate free cash flow, which currently stands at $0.00 billion. Potential investors should carefully evaluate the company's turnaround strategy and its ability to improve profitability and cash flow generation. Upcoming catalysts may include new product launches or expansion into new markets, but these need to be weighed against the potential risks associated with the company's financial performance.

Branchenkontext

Integrated BioPharma operates in the packaged foods industry, specifically within the vitamins and supplements segment. This market is characterized by increasing consumer awareness of health and wellness, driving demand for nutritional products. The industry is competitive, with established players and emerging brands vying for market share. Trends include personalized nutrition, clean label products, and e-commerce distribution. Integrated BioPharma's focus on contract manufacturing and distribution positions it within the supply chain, serving both large distributors and specialized healthcare providers. The company's success depends on its ability to maintain quality, innovate with new products, and adapt to changing consumer preferences.

Packaged Foods

Consumer Defensive

Wachstumschancen

Expansion of Contract Manufacturing Services: Integrated BioPharma can capitalize on the growing demand for private label and white label supplements by expanding its contract manufacturing services. The global contract manufacturing market for nutraceuticals is projected to reach $95 billion by 2028. By investing in advanced manufacturing technologies and quality control processes, INBP can attract more clients and increase its production volume, leading to higher revenue and improved profitability. This expansion could be realized within the next 2-3 years.
New Product Development and Innovation: Introducing innovative and scientifically-backed nutritional supplements can drive revenue growth. The market for personalized nutrition is expanding rapidly, with consumers seeking customized solutions for their health needs. Integrated BioPharma can invest in research and development to create new products targeting specific health conditions or demographic groups. Successful product launches could significantly boost sales within the next 1-2 years.
Geographic Expansion into New Markets: Expanding its distribution network beyond the United States and Luxembourg can unlock new growth opportunities. Emerging markets in Asia and Latin America are experiencing increasing demand for vitamins and supplements. By establishing partnerships with local distributors or setting up its own sales channels, Integrated BioPharma can tap into these high-growth markets. This expansion could take 3-5 years to fully materialize.
Strategic Acquisitions and Partnerships: Acquiring complementary businesses or forming strategic partnerships can enhance Integrated BioPharma's capabilities and market reach. For example, acquiring a company with expertise in e-commerce or digital marketing can improve its online sales channels. Partnering with a research institution can accelerate its product development efforts. Such strategic moves could yield significant benefits within the next 2-3 years.
Focus on E-commerce and Direct-to-Consumer Sales: The shift towards online shopping presents a significant growth opportunity for Integrated BioPharma. By investing in its e-commerce platform and digital marketing capabilities, the company can reach a wider customer base and increase its direct-to-consumer sales. The online channel offers higher margins and greater control over the customer experience. This strategy can be implemented and generate results within the next 1-2 years.

Market Cap of $0.01B indicates a micro-cap company with potential for high growth but also higher risk.
Negative Profit Margin of -0.4% highlights challenges in achieving profitability.
Gross Margin of 7.8% is relatively low compared to industry averages, suggesting potential inefficiencies in production or pricing.
Debt-to-Equity Ratio of 2.55 indicates a highly leveraged balance sheet, which could increase financial risk.
Beta of 0.52 suggests the stock is less volatile than the overall market.

Was das Unternehmen tut

Manufactures vitamins and nutritional supplements.
Distributes vitamins, nutritional supplements, and herbal products.
Markets vitamins, nutritional supplements, and herbal products.
Offers contract manufacturing services to distributors.
Provides warehousing and fulfillment services.
Distributes raw materials for supplement production.

Geschaeftsmodell

Contract manufacturing of vitamins and supplements for other companies.
Direct distribution of branded and white-label products.
Warehousing and fulfillment services for nutraceutical businesses.

Distributors of vitamins and supplements.
Multilevel marketing companies.
Specialized healthcare providers.
Consumers (potentially through retail channels).

Established manufacturing capabilities.
Existing distribution network.
Long-standing relationships with suppliers and customers.

Katalysatoren

Upcoming: Potential new product launches in the vitamin and supplement sector.
Upcoming: Expansion into new geographic markets, particularly in Asia.
Ongoing: Increasing consumer demand for health and wellness products.
Ongoing: Growth in the contract manufacturing market for nutraceuticals.
Ongoing: Shift towards e-commerce and direct-to-consumer sales channels.

Risiken

Potential: Intense competition from larger, more established players.
Potential: Fluctuations in raw material prices.
Potential: Changes in regulations governing the nutraceuticals industry.
Ongoing: Low profit margins and high debt levels.
Ongoing: Limited liquidity and price volatility due to OTC listing.

Staerken

Established manufacturing capabilities.
Existing distribution network.
Experience in contract manufacturing.
Presence in both US and Luxembourg markets.

Schwaechen

Low profit margin.
High debt-to-equity ratio.
Small market capitalization.
Limited brand recognition.

Chancen

Expansion of contract manufacturing services.
New product development and innovation.
Geographic expansion into emerging markets.
Increased focus on e-commerce and direct-to-consumer sales.

Risiken

Intense competition in the nutraceuticals market.
Changing consumer preferences and regulatory requirements.
Fluctuations in raw material prices.
Potential product liability claims.

Wettbewerber & Vergleichsunternehmen

GNC Holdings, Inc. — Focuses on retail sales of vitamins and supplements. — (GNC)
Herbalife Nutrition Ltd. — Utilizes a multi-level marketing distribution model. — (HLF)
USANA Health Sciences, Inc. — Develops and manufactures nutritional supplements and personal care products. — (USNA)

Key Metrics

Volume: 0
MoonshotScore: 40/100

Company Profile

Headquarters: Hillside, United States
Employees: 153

AI Insight

AI analysis pending for INBP

OTC Tier: OTC Other
Disclosure Status: Unknown

Fragen & Antworten

What does Integrated BioPharma, Inc. do?

Integrated BioPharma, Inc. operates in the consumer defensive sector, focusing on the manufacturing, distribution, and marketing of vitamins, nutritional supplements, and herbal products. The company functions through two segments: Contract Manufacturing, where it produces supplements for other companies, and Other Business Lines, which includes warehousing, fulfillment, and raw material distribution. This dual approach allows Integrated BioPharma to serve both B2B clients and potentially reach end consumers, primarily in the United States and Luxembourg. The company's business model is centered around providing a range of health and wellness products and services within the nutraceuticals market.

What do analysts say about INBP stock?

As of 2026-03-16, formal analyst coverage of Integrated BioPharma, Inc. (INBP) may be limited due to its small market capitalization and OTC listing. Key valuation metrics, such as price-to-earnings ratio, may not be readily available or meaningful due to the company's negative profit margin. Growth considerations would focus on the company's ability to improve profitability, expand its product offerings, and penetrate new markets. Investors should conduct their own due diligence and consider the risks associated with investing in a micro-cap OTC stock.

What are the main risks for INBP?

Integrated BioPharma, Inc. faces several risks inherent to its industry and business model. Intense competition from larger, more established players in the nutraceuticals market poses a significant challenge. Fluctuations in raw material prices can impact the company's profitability. Changes in regulations governing the production and marketing of vitamins and supplements could also create compliance costs. Additionally, the company's low profit margins, high debt levels, and OTC listing contribute to financial and liquidity risks.

Is INBP a good investment right now?

Use the AI score and analyst targets on this page to evaluate Integrated BioPharma, Inc. (INBP). Our analysis considers fundamentals, technicals, and market sentiment to help you decide.

What is the MoonshotScore for INBP?

The MoonshotScore is a proprietary 0-100 AI rating that evaluates Integrated BioPharma, Inc. across multiple dimensions including financial health, growth trajectory, and risk factors.

Where can I find INBP financial statements?

Integrated BioPharma, Inc. financial data including revenue, earnings, and balance sheet metrics are available in the Financials tab on this page, sourced from institutional-grade data providers.

What do analysts say about INBP?

Analyst consensus targets and ratings for Integrated BioPharma, Inc. are shown in the analysis section. These are aggregated from major Wall Street firms and updated regularly.

How volatile is INBP stock?

Check the beta and historical price range on this page to assess Integrated BioPharma, Inc.'s volatility relative to the broader market.